AAN 2026: J&J, Kyverna, Capricor and Praxis Showcase Practice-Changing Data

Why It Matters

These advances could reshape treatment algorithms for autoimmune neuromuscular disorders and rare muscle diseases, offering longer‑lasting efficacy and steroid‑sparing options while opening sizable market opportunities.

Key Takeaways

• J&J's Imaavy shows 2‑year symptom control in gMG patients
• 60% of Imaavy users reduced corticosteroid dosage to ≤5 mg daily
• Kyverna's miv‑cel achieved complete B‑cell depletion and steroid‑free status
• Capris' ulixacaltamide targets >$3 billion essential tremor market
• Capricor's deramiocel slowed Duchenne upper‑limb decline by up to 83%

Pulse Analysis

The American Academy of Neurology’s 2026 gathering highlighted a wave of innovative therapeutics that could redefine care for neuromuscular disorders. Johnson & Johnson’s FcRn antagonist Imaavy demonstrated durable efficacy over 120 weeks, reinforcing its role as a steroid‑sparing option for generalized myasthenia gravis. Meanwhile, Kyverna’s autologous CAR‑T platform, miv‑cel, delivered an unprecedented immune reset, eradicating B cells and eliminating the need for conventional immunosuppressants in a small but compelling cohort. Together, these data suggest a shift toward biologics that target disease mechanisms more precisely, potentially reducing long‑term toxicity.

In the realm of rare muscle disease, Capricor Therapeutics leveraged a proprietary cardiac‑cell subset to create deramiocel, a cell‑based therapy that markedly decelerated functional loss in Duchenne muscular dystrophy. The HOPE‑3 trial’s 54% to 83% slowdown in upper‑limb decline underscores the therapeutic promise of regenerative approaches, even as the FDA’s August decision looms. Successful approval would not only validate cell‑therapy pipelines but also set a precedent for re‑filing strategies after prior regulatory setbacks, encouraging investment in next‑generation treatments for orphan indications.

Essential tremor, a disorder affecting millions, is poised for disruption thanks to Praxis Medicines’ ulixacaltamide. Phase 3 results confirmed a robust 4.3‑point improvement on functional scales, with sustained response in over half of continued‑treatment patients. Analysts project a market exceeding $3 billion, reflecting both unmet patient needs and the drug’s differentiated calcium‑channel blockade. If approved by early 2027, ulixacaltamide could catalyze further neuro‑pharma innovation, prompting competitors to explore similar mechanisms and expanding therapeutic options for movement disorders.